| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS42001719 | EBV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS10006549 | HBV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS10008067 | HBV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS10008068 | HBV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30003991 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30079115 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30087748 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30081211 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30081546 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS30082146 | HIV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | EGFR |
|---|---|
| DrugBank ID | DB00317 |
| Drug Name | Gefitinib |
| Target ID | BE0000767 |
| UniProt ID | P00533 |
| Regulation Type | antagonist |
| PubMed IDs | 10815932; 11522647; 11566608; 11585753; 11673690; 11752352 |
| Citations | Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000 May;6(5):2053-63.@@Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Rosello J, Nicholson RI, Mendelsohn J, Baselga J: Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res. 2001 Sep 1;61(17):6500-10.@@Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM: Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer. 2001 Sep;8(3):175-82.@@Moasser MM, Basso A, Averbuch SD, Rosen N: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001 Oct 1;61(19):7184-8.@@Arteaga CL, Johnson DH: Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol. 2001 Nov;13(6):491-8.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved; Investigational |
| Direct Classification | Quinazolinamines |
| SMILES | COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1 |
| Pathways | Gefitinib Action Pathway |
| PharmGKB | PA131301952 |
| ChEMBL | CHEMBL939 |
